NCT01283035: A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer |
|
|
| Completed | 2 | 6 | US | Akt Inhibitor MK2206, MK2206, Laboratory Biomarker Analysis | National Cancer Institute (NCI) | Ovarian Sarcoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma | 12/14 | 12/14 | | |
